<DOC>
	<DOCNO>NCT02629289</DOCNO>
	<brief_summary>This study healthy participant . This study test single dose research drug HSP-130 two exist approve drug United States - approve Neulasta European Union-approved Neulasta .</brief_summary>
	<brief_title>A Comparative Study Evaluate Effect HSP-130 , US-approved Neulasta EU-approved Neulasta Healthy Participants</brief_title>
	<detailed_description>There 25 healthy participant six sequence group . A total 150 participant study one site Australia . In addition 150 participant include , alternate subject ask come site day prior dose schedule begin . There 3 treatment option 3 study dose period ( 1 , 2 3 ) least 56 day treatment . The subject ask take part study assign chance ( randomize ) one sequence group mention ( 1 , 2 , 3 , 4 , 5 , 6 ) .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>1 . Provides write informed consent approve Independent Ethics Committee ( IEC ) prior study related activity 2 . Healthy male female volunteer 18 65 year age ( inclusive ) 3 . Body mass index ( BMI ) 19 30 kg/m^2 , inclusive , body weight &lt; 50 kg &gt; 100 kg 4 . Nonsmoker ( define subject smoke used nicotine contain product least 3 month prior study drug administration negative urine screen cotinine ) Screening 5 . Female subject childbearing potential male subject partner childbearing potential , agree pregnancy prevention throughout duration study ( Followup Visit ) . Subjects partner must agree use effective method contraception , avoid impregnation female throughout course study . Subjects use oral contraceptive must stable regimen least 3 month prior Screening . Adequate form contraception use include hormonal contraceptive ( oral , patch , depot ) , intrauterine device ( IUD ) , barrier contraceptive method , diaphragm , cervical cap/shield , male condom female condoms.Sexually active subject must use contraception study drug admission Followup Visit . Male subject must also refrain donate sperm admission Followup visit 6 . Willing able comply requirement protocol available plan duration study 1 . Any active systemic immunologic disease condition , include limit follow general category : cardiovascular/pulmonary , hepatorenal , systemic infection , lactation 2 . History , current , malignancy exception adequately treat squamous basal cell carcinoma skin cervical carcinoma situ within 5 year 3 . Any disease condition might interfere absorption , distribution , metabolism , excretion study drug would place subject increase risk 4 . Hematologic laboratory abnormality include leukocytosis ( defined total leukocytes &gt; 11,000/μL ) , leukopenia ( define total leukocyte &lt; 4000/μL ) , neutropenia ( define ANC &lt; 1500/μL ) thrombocytopenia ( defined platelet count &lt; 150/μL ) 5 . Clinically significant , judged investigator , vital sign 12lead ECG abnormality 6 . History biological growth factor exposure , include limited filgrastim granulocytecolony stimulate factor context treatment , prophylaxis , peripheral blood stem cell mobilization , previous investigational study set . This also include exclusion history interferon , epoetin , intravenous immunoglobulin ( IVIG ) exposure 7 . Receipt live vaccination , exposure communicable viral disease , varicella , mumps , measles within 4 week prior Screening 8 . Surgery within 4 month prior Screening 9 . Use prescription medicine ( exception contraceptive ) within 7 day least 5 halflives , whichever longer . Use oral parenteral anticoagulant antiplatelet agent corticosteroid specifically query 10 . Administration drug depot injection ( exception depot contraception ) within 30 day prior Randomization 5 halflives drug , whichever longer 11 . Use counter medication , include aspirin nonsteroidal antiinflammatory drug , natural preparation ( dietary supplement herbal product ) within 7 day least 5 halflives , whichever longer . Vitamins calcium allow ( exceed 100 % Daily Value ) 12 . History drug alcohol abuse within 2 year prior Randomization , determine investigator positive urine screen drug abuse ( UDS ) Screening . Screening drug abuse minimally include cannabinoids , opiate , barbiturate , amphetamine , cocaine , benzodiazepine , alcohol 13 . Drug sensitivity , allergic reaction , know hypersensitivity/idiosyncratic reaction Escherichia coliderived protein , filgrastim , granulocytecolony stimulating factor , pegylated agent 14 . History splenic rupture ( subject asplenic ) , pulmonary infiltrate pneumonia , sickle cell disease , chronic neutropenia , thrombocytopenia , vasculitis 15 . Any clinically significant , determined investigator , abnormal laboratory evaluation , include human immunodeficiency virus antibody ( HIVAb ) , hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) , liver function include alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 1.5 upper limit normal take Screening . Negative HIVAb status confirm Screening result maintain confidentially study site 16 . Donated lose 475 mL blood volume ( include plasmapheresis ) transfusion blood product within 3 month prior Screening 17 . Participated another clinical research study administration investigational drug within 30 day prior Randomization 18 . Potentially able comply requirement clinical trial , communicate effectively study personnel , consider Investigator , reason , unsuitable candidate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HSP-130</keyword>
	<keyword>Pharmacodynamic Pharmacokinetic equivalence</keyword>
	<keyword>Pegfilgrastim</keyword>
</DOC>